KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Noninferiority Study of Purified Vero Rabies Vaccine-Serum Free in 3-dose and 2-dose Preexposure Prophylaxis Regimens in Comparison With Licensed Rabies Vaccines.

Kulkanya Chokephaibulkit, Catherine Huoi, Terapong Tantawichien, Piroon Mootsikapun, Pope Kosalaraksa, Sasisopin Kiertiburanakul, Winai Ratanasuwan, Manuel Vangelisti, Thelma Laot, Youjun Huang, Celine Petit, Andrea-Clemencia Pineda-Peña, Carina Frago

Clin Infect Dis 81(3) 654-666

PMID39587931
PMCIDPMC12497947
DOI10.1093/cid/ciae581
发表日期2024-11-26
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

BACKGROUND: A next-generation, serum-free, highly purified Vero cell rabies vaccine, PVRV-NG2, is in development. METHODS: This multicenter, observer-blind, phase 3 study evaluated the immunogenicity and safety of PVRV-NG2, compared with 2 licensed rabies vaccines (purified Vero cell rabies vaccine [PVRV] and human diploid cell vaccine [HDCV]), as a preexposure prophylaxis (PrEP) regimen. Participants were randomized 3:1:1 to PVRV-NG2, PVRV, or HDCV, as a 3-dose (cohort 1; children and adults; day [D] 0, D7, and D28) or 2-dose (cohort 2; adults; D0 and D7) PrEP regimen. The primary objective was noninferiority of PVRV-NG2 to PVRV and HDCV as 3-dose PrEP, based on the proportion of participants with rabies virus-neutralizing antibody titer ≥0.5 IU/mL at D42. Noninferiority of immune responses for 2-dose PrEP at D28 and noninferiority of 2-dose (D28) versus 3-dose (D42) HDCV were also assessed as secondary immunogenicity objectives. Safety was assessed throughout. RESULTS: Overall, 1708 participants were enrolled (cohort 1: 505 children, 505 adults; cohort 2: 698 adults). All participants had rabies virus-neutralizing antibody titers ≥0.5 IU/mL after 3-dose PVRV-NG2 (D42), with noninferiority to PVRV and HDCV demonstrated. All secondary immunogenicity objectives were achieved, including noninferiority of 2-dose PVRV-NG2 versus 2-dose PVRV and HDCV (D28) and 3-dose HDCV (D42), and noninferiority of 2-dose HDCV versus 3-dose HDCV. The safety profile of PVRV-NG2 was comparable to those of PVRV and HDCV. CONCLUSIONS: This study supports the use of PVRV-NG2 in 2- or 3-dose PrEP regimens, with no safety concerns identified. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier: NCT04127786; EudraCT: 2019-000973-22; WHO: U1111-1217-3241.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractGraphical Abstract
非 KM Figure
Figure 1Figure 1. Proportion of participants (95% CI) with RVNA titer ≥0.5 IU/mL with the 3-dose PrEP primary series (cohort 1, overall population, pooled children and adults) (PPAS). CI, confidence interval; D, day; HDCV, human diploid cell vaccine; PPAS, per-protocol analysis set; PrEP, preexposure prophylaxis; PVRV, purified Vero cell rabies vaccine; PVRV-NG2, next-generation purified Vero cell rabies vaccine; RVNA, rabies virus neutralizing antibody.
非 KM Figure
Figure 2Figure 2. RVNA GMT (95% CI) in participants receiving the 3-dose PrEP primary series (cohort 1, overall population, pooled children and adults) (PPAS). CI, confidence interval; D, day; GMT, geometric mean titer; HDCV, human diploid cell vaccine; PPAS, per-protocol analysis set; PrEP, preexposure prophylaxis; PVRV, purified Vero cell rabies vaccine; PVRV-NG2, next-generation purified Vero cell rabies vaccine; RVNA, rabies virus neutralizing antibody.
非 KM Figure